SLC7A11: a New Potential Therapeutic Target via Induced Ferroptosis in Tumors!
SLC7A11: a New Potential Therapeutic Target via Induced Ferroptosis in Tumors!Lately, Cell (Impact Factor=66.850) released "Ferroptosis" review to mark the ten-year anniversary of the discovery of ferroptosis [1]! The article focuses on the key regulators of this form of cell death, which promise ...
Detailed information

A Review of WFDC8 Antibody
A Review of WFDC8 AntibodyProduct Name: WFDC8 antibody Code:  CSB-PA818226LA01HU I am Dr. Ferran Barrachina, currently a postdoctoral fellow at the Massachusetts General Hospital and Harvard Medical School in Boston (United States). My r...
Detailed information

A Review of A Human NGAL ELISA Kit
A Review of A Human NGAL ELISA KitProduct Name: Human neutrophil gelatinase-associated lipocalin, NGAL ELISA Kit Code: CSB-E09408h We used the Elisa kit CSB-E09408h for the assessment of NGAL concentration in urine samples of children, adults and chr...
Detailed information

CLDN4: A Potential Prognostic Indicator and Therapeutic Target in Tumors!
CLDN4: A Potential Prognostic Indicator and Therapeutic Target in Tumors!Presently, a paper entitled "TGF-β induces GBM mesenchymal transition through upregulation of CLDN4 and nuclear translocation to activate TNF-α/NF-κB signal pathway" was published on Cell Death...
Detailed information

Intestinal Mucosal Barrier Bodyguard --ALPi
Intestinal Mucosal Barrier Bodyguard --ALPiAlkaline phosphatase: Alkaline phosphatase (AKP/ALP/AP) is a monobasic phosphohydrolase that widely distributes in human liver, bone, intestine, kidney, placenta and other tissues, and is excreted out of the gallbladd...
Detailed information

ZG16B: A New Tumor Biomarker Offers Important Insights for Drug Development in Pancreatic Cancer!
ZG16B: A New Tumor Biomarker Offers Important Insights for Drug Development in Pancreatic Cancer!ZG16B has recently emerged as a novel oncogene based on comprehensive bioinformatics analysis. Apparently, treatment of malignancies has experienced immense progress through immunotherapy. But the success of immunotherap...
Detailed information

Proteolysis Targeting Chimera (PROTAC): A
Proteolysis Targeting Chimera (PROTAC): A "Revolutionary" Technology in Small Molecule Drug Discovery!Today, progress is widely being made in targeted cancer therapy. Most current drug targets are G-protein coupled receptors, nuclear receptors, ion channels or enzymes. Nevertheless, up to 80% of proteins remain “undrug...
Detailed information

How to Validate An Antibody?
How to Validate An Antibody?With the progress of science and medicine, antibodies have become potent tools to recognize, detect, isolate, or visualize their corresponding antigens in basic science research and clinical assays. Whether or not antibo...
Detailed information

RSPO1: The key factor determining
RSPO1: The key factor determining "battle of the sexes " is “favored” in the culture of organoids?Gender is much more complicated than it seems. There is increasing evidence that gender is not a simple dualism. For years, scientists have believed that female development is the default process, while male development ...
Detailed information

DDR1: a Novel Member of the RTKs Family, a Potential Target for Tumor Therapy!
DDR1: a Novel Member of the RTKs Family, a Potential Target for Tumor Therapy!DDR1 has been newly identified as a member of the receptor tyrosine kinases (RTKs) family. It is widely recognized that RTKs control cell proliferation and differentiation, which are involved in tumorigenesis. Therefore,...
Detailed information

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1